Assessment of Efficacy of Mirabegron, a New beta3-adrenergic Receptor in the Prevention of Heart Failure

Inclusion Criteria: * Age between 18 and 90 years * Arterial hypertension on stable therapy according to current guideline algorithms (including stable medication for at least four weeks before inclusion), * Morphological signs of structural cardiac remodelling by echocardiography, i.e. increased LV mass index (110 g/m2 or higher for female; 134 g/m2 or higher for male subjects (Devereux, Reichek 1977)) or end-diastolic wall thickness \> or equal to 13 mm in at least one wall segment * Patients may have atrial fibrillation (AF), but with well-regulated ventricular response, i.e. heart rate\<100/min (RACE II - (Groenveld et al. 2013, 2013)), * Written informed consent * For subjects unable to read and/or write, oral informed consent observed by an independent witness is acceptable if the subject has fully understood oral information given by the Investigator. The witness should sign the consent form on behalf of the subject. Exclusion Criteria: * Unstable hypertension with systolic BP≥160 mm Hg and/or diastolic BP≥100 mm Hg (based on office measurement, not ambulatory measurement) * Documented ischemic cardiac disease * History of hospitalization for overt heart failure within last 12 months * Patients after heart transplantation * Genetic hypertrophic or dilated cardiomyopathy * Dysthyroidism. * Severe valvulopathy * NYHA-class \> II * BMI \>40 kg/m2 * EF \< 50%, regardless of symptoms * Known other cause (i.e. COPD) of respiratory dysfunction; patients under positive pres…